Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Announces successful dosing of first test subjects in a randomised, placebo-controlled phase 1a clinical trial for lead programme SDC-1801. SDC-1801 is a dual TYK2/JAK1 kinase inhibitor and potential new therapeutic for various autoimmune diseases with an initial focus on psoriasis. The phase 1a trial will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SDC-1801 in healthy subjects, in single and multiple ascending oral dose studies. Dosing has started in a specialist clinical unit in Melbourne, Australia. Sareum expects full safety data to become available during the first half of 2024, after which a phase 1b clinical study will commence post-haste if the Phase 1a trial obtains satisfactory results.

Chief Executive Officer Tim Mitchell says: "Dual TYK2 and JAK1 inhibition offers significant potential benefits for immune health and we believe by targeting both these pathways, SDC-1801 could have the potential for superior efficacy in autoimmune disease compared to agents that block just one of the two kinases. Dosing of the first subjects in this trial is an important first step to establishing the safety and tolerability profile of SDC-1801 and we look forward to watching the trial progress."

Current stock price: 130.30 pence, down 3.5% in London on Tuesday

12-month change: down 41%

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.